Advanced CardioVascular Consultants — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2023	Research	$146	2
2021	Research	$152	1
2019	Research	$6,352	3

Breakdown

Who paid Research payments · program years 2019–2023

AstraZeneca Pharmaceuticals LP $4,796 1 payment
Kowa Research Institute, Inc. $1,328 1 payment
Merck Sharp & Dohme Corporation $526 4 payments

Studies the money was for Research payments · program years 2019–2023

A Multinational Randomised Double Blind Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death Myocardial Infarction or Stroke in Patients with Type 2 Diabetes $4,796 1 payment
K-877-302 $1,328 1 payment
TECOS A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination Oral Antihyperglycemic Therapy $380 2 payments
TECOS# A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination Oral Antihyperglycemic Therapy $146 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.